Survival analysis in clinical trials: past developments and future directions.
about
Mutant LRRK2 toxicity in neurons depends on LRRK2 levels and synuclein but not kinase activity or inclusion bodiesNovel image markers for non-small cell lung cancer classification and survival predictionEstimating Cure Rates From Survival Data: An Alternative to Two-Component Mixture ModelsDynamic tumor modeling of the dose-response relationship for everolimus in metastatic renal cell carcinoma using data from the phase 3 RECORD-1 trial.Semiparametric models: a generalized self-consistency approach.Modified hybrid stem fixation in revision TKA is durable at 2 to 10 years.Predictors of nursing home residents' time to hospitalizationThe role of covariates in estimating treatment effects and risk in long-term clinical trials.Identifying polyglutamine protein species in situ that best predict neurodegenerationAssociation between well-known histopathological criteria and overall survival in invasive ductal carcinoma.High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 PatientsAssociation of Escherichia coli J5-specific serum antibody responses with clinical mastitis outcome for J5 vaccinate and control dairy cattlePrediction of high risk for death in patients with follicular lymphoma receiving rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in first-line chemotherapy.Treatment of canine mast cell tumours with vinblastine, cyclophosphamide and prednisone: 35 cases (1997-2004).Designing multiregional trials under the discrete random effects model.Dental implant suprastructures using cobalt-chromium alloy compared with gold alloy framework veneered with ceramic or acrylic resin: a retrospective cohort study up to 18 years.H-likelihood approach for joint modeling of longitudinal outcomes and time-to-event data.Reduced PTEN protein expression and its prognostic implications in canine and feline mammary tumors.An accumulator model for responses and response times in tests based on the proportional hazards model.A latent trait model for response times on tests employing the proportional hazards model.A competing risk approach to the analysis of trials of alternative intra-uterine devices (IUDs) for fertility regulation.
P2860
Q24318474-9878ADDC-B0EF-4626-9055-4970FE5C4403Q28385611-AEF49D7D-834B-47B8-ABEF-B4D840803CB9Q33769257-CF13F09C-62C6-4FDE-B414-C50F1E457E13Q34348318-F392AA0B-3AE7-474D-8CA9-8EC2B6FD6186Q34365276-250A57F3-DB19-4C10-B535-C2AE4020BE13Q34548037-072F87E7-3985-4C7E-8DE5-685B93EB5B1DQ34554679-52E06702-0D33-4ABA-BFB1-BA25873A8F65Q34906676-E4CE97EC-85E5-4CD6-9CC2-7375E4B80B1BQ35729286-98812E3F-7DA2-475B-B865-C4C8A7C73DEFQ36262173-6227C25F-31B9-4EF2-91D1-A0940612DA87Q36948373-EE0793D8-E4F4-41D7-80E4-2D9E0849B5E3Q37099238-595E87B4-6916-408A-B315-ACE6C03059EEQ39739502-CB452AA4-99F6-44C5-A64B-C1D063A90AFEQ43276493-D8C40E39-122A-47F1-BAAB-36B18F69BBEEQ43513430-9BA56063-699F-4463-A21C-4602116FC131Q45898574-1568965F-2174-4366-AAB2-C38C3853702AQ47594027-CCDC0829-63B7-47EA-9057-3F3B08AF938EQ47834443-3AA9BC60-F9E3-4EBE-ACD1-103BDE22E354Q47855390-BE7B09DB-F07F-4F4E-BE81-3C0987DB458EQ51514942-BE920E87-58B2-4F7A-9F05-5525F52D9447Q52050117-9D740DE9-1ECD-4847-9244-DA4EE8561E2B
P2860
Survival analysis in clinical trials: past developments and future directions.
description
2000 nî lūn-bûn
@nan
2000 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Survival analysis in clinical trials: past developments and future directions.
@ast
Survival analysis in clinical trials: past developments and future directions.
@en
Survival analysis in clinical trials: past developments and future directions.
@nl
type
label
Survival analysis in clinical trials: past developments and future directions.
@ast
Survival analysis in clinical trials: past developments and future directions.
@en
Survival analysis in clinical trials: past developments and future directions.
@nl
prefLabel
Survival analysis in clinical trials: past developments and future directions.
@ast
Survival analysis in clinical trials: past developments and future directions.
@en
Survival analysis in clinical trials: past developments and future directions.
@nl
P2860
P1433
P1476
Survival analysis in clinical trials: past developments and future directions.
@en
P2093
P2860
P304
P356
10.1111/J.0006-341X.2000.0971.X
P407
P577
2000-12-01T00:00:00Z